Table of Contents

All the data and content are powered by ZXData, Learn more about ZXData

ZX Data private stock trade

Executive Summary

  • This quarter, reporting holders marked up their private portfolios by 3.5% ($ weighted) with an average mark-up of 3.4% (equal weighted).
  • Sentiment up:
  • Sentiment down:
  • In January, 27% of companies with ZX Index Values showed a difference of 10% or less compared to Fund Marks, and 42% of companies with ZX Index Values showed a difference of 20% or less compared to Fund Marks.

Heat Map: October 31st, 2024 Reporting Period

3.5%

Appreciation/Depreciation of All Reported Holdings1

3.4%

Average Mark-Up/Mark-Down Across All Reported Holdings2
Adimab
260.5%
Lightmatter
152.3%
xAI
80.9%
Rad Power
39.7%
Lime
38.8%
X Holdings
38.5%
goPuff
33.6%
Locus Robotics
26.1%
CoreWeave
25.9%
Anthropic
24.8%
Arctic Wolf
24.0%
SambaNova
22.0%
Algolia
21.9%
Xsight Labs
21.5%
Bolt
21.2%
FLEXE
19.8%
Databricks
19.1%
Canva
18.4%
Magic Leap
16.7%
KoBold Metals
15.8%
Anduril
14.2%
Signifyd
13.6%
PsiQuantum
13.2%
Celonis
13.1%
Figma
12.8%
Omada Health
12.8%
VAST Data
12.0%
Unqork
11.8%
MNTN
11.3%
Moloco
10.6%
Farmers Business Network
9.5%
Bytedance
8.5%
Caidya (dMed)
7.4%
Rappi
6.5%
Bombas
6.1%
Skyryse
6.0%
Dataminr
5.8%
Epic Games
5.8%
Asapp
5.4%
Klarna
4.7%
BETA Technologies
4.4%
SpaceX
4.4%
Pine Labs
4.2%
Ant Group
4.0%
Roofstock
4.0%
Applied Intuition
3.7%
Tarana
2.9%
Fanatics
2.7%
Caris
0.8%
Wugen
0.7%
Color Genomics
0.6%
Tanium
0.6%
Sila Nano
0.5%
Waymo
0.5%
Cellanome
0.4%
Checkr
0.4%
Clio
0.2%
A24 Films
0.0%
Altos Labs
0.0%
Bright Peak
0.0%
Chime
0.0%
Diamond Foundry
0.0%
EndeavorBio
0.0%
Epirus
0.0%
Fabletics
0.0%
Freenome
0.0%
GOAT
0.0%
Goop
0.0%
Gusto
0.0%
HaulHub
0.0%
Laronde
0.0%
Mirador Therapeutics
0.0%
PrognomIQ
0.0%
Quell
0.0%
Rapyd
0.0%
RefleXion Medical
0.0%
Scorpion Therapeutics
0.0%
SecurityScorecard
0.0%
ServiceTitan
0.0%
Snyk
0.0%
Stripe
0.0%
Tipalti
0.0%
T-Knife
0.0%
Zipline
0.0%
Conformal Medical
-0.1%
FogPharma
-0.1%
Odyssey Therapeutics
-0.1%
Sonoma Bio
-0.1%
Tenstorrent
-0.1%
Ankyra
-0.2%
Cardurion
-0.2%
Socure
-0.3%
Inscripta
-0.4%
Cleerly
-0.5%
JUUL
-0.5%
Kartos Therapeutics
-0.5%
Medical Micro
-0.5%
Retym
-0.5%
Meesho
-0.7%
Lenskart
-0.9%
Verily
-1.0%
Astranis
-1.1%
Akeana
-1.8%
Faraday Pharma
-2.6%
Circle
-3.0%
YuLife
-3.1%
Honor Tech
-3.3%
Grammarly
-3.6%
Castle Creek
-3.7%
Alif Semi
-3.8%
SiMa ai
-3.8%
Kardium
-4.0%
Saluda Medical
-4.1%
VideoAmp
-4.1%
Aledade
-4.3%
Druva
-4.6%
Liquid Death
-4.6%
Deep Genomics
-4.9%
Insightec
-5.6%
Tory Burch
-5.9%
Skyhawk
-6.2%
AgomAb Therapeutics
-6.9%
GupShup
-7.2%
Evozyne
-7.4%
Genesis Therapeutics
-7.4%
Redwood Materials
-7.6%
City Therapeutics
-7.7%
Dragonfly Therapeutics
-8.1%
Enevate
-8.3%
Menlo Micro
-8.6%
MasterClass
-9.0%
Generate Bio
-9.1%
Treeline Bio
-9.6%
Discord
-10.3%
Element Bio
-10.3%
Nuro
-10.5%
ElevateBio
-11.6%
Galvanize
-11.8%
Starling Bank
-12.8%
Cross River
-13.4%
DataRobot
-14.3%
Savage X
-14.4%
Blink Health
-15.1%
Candid
-16.0%
CelLink
-17.6%
Insitro
-18.4%
Resilience
-18.7%
DNA Script
-21.5%
Asimov
-33.5%
Thriveworks
-49.4%
LifeMine
-64.4%
Einride
-68.3%
SalioGen
-95.0%
Relativity Space
-96.2%

1 Dollar-weighted return on all reported holdings
2 Equal-weighted mark-up or mark-down across all reported holdings

This quarter, reporting holders marked up their private portfolios by 3.5% ($ weighted) with an average mark-up of 3.4% (equal weighted).

Adimab experienced the most significant mark-up, followed by Lightmatter, xAI and Rad Power. CloudTech & DevOps, AI & Machine Learning and FoodTech saw the largest mark-ups across sectors.

Relativity Space saw the largest mark-down followed by SalioGen, Einride and LifeMine. Among sectors, BioTech, Logistics & Transportation and HealthTech saw the largest mark-downs.

Comparison of ZX Index Value vs. Fund Marks

CompaniesRobustness Score3ZX Index Values4 vs. Fund Marks
Anthropic6+77.90%
SpaceX8+67.10%
Checkr1+62.30%
Redwood Materials1+60.30%
Sila Nano2+58.20%
GupShup2+47.90%
Socure1+42.10%
Aledade4+38.90%
CoreWeave7+31.00%
Stripe8+27.60%
Anduril7+25.80%
DataRobot1+25.30%
Meesho1+25.10%
Blink Health1+19.10%
Figma5+19.00%
Signifyd2+16.50%
VAST Data5+16.40%
Chime6+9.20%
xAI8+8.70%
Cross River5+5.90%
Tanium1+3.30%
Klarna8+0.30%
Databricks7-0.30%
Canva5-0.50%
Discord6-3.10%
Waymo1-3.40%
Lightmatter5-3.70%
Moloco1-6.00%
Bolt4-6.70%
Tenstorrent4-8.20%
Circle2-8.40%
Omada Health1-15.80%
SambaNova6-16.00%
Liquid Death3-19.60%
Dataminr1-20.00%
Gusto6-22.40%
Arctic Wolf2-28.50%
Freenome2-29.60%
Celonis4-30.80%
KoBold Metals2-31.40%
Epic Games5-32.10%
Zipline3-32.80%
Locus Robotics1-34.20%
Bytedance6-36.20%
Algolia2-39.00%
Druva1-41.20%
Rapyd4-41.60%
Snyk1-43.40%
Fanatics2-43.40%
MNTN1-46.00%
VideoAmp1-51.80%
Altos Labs2-71.90%

3 ZXData Robustness Score is an internally developed metric to assign confidence levels to the underlying data used in constructing ZXData output metrics. The ZXData Robustness Score is calculated on a scale of 1 to 10 for each company, based on the number of executed trades, number of buy and sell orders submitted to ZX and skewness of the order book.
4 ZX Index Value is an internally developed metric that reflects secondary values for private companies using an algorithmic approach based on the values sourced from ZX and ZXData partners. The algorithm used to calculate ZX Index Values incorporates both executed transaction values and bid and ask pricing.

In January, 27% of companies with ZX Index Values showed a difference of 10% or less compared to Fund Marks, and 42% of companies with ZX Index Values showed a difference of 20% or less compared to Fund Marks. Among the companies, Anthropic, SpaceX and Checkr had the highest positive variance in reported marks versus ZX Index Values. Altos Labs, VideoAmp and MNTN had the highest negative variance in reported marks versus ZX Index Values.

Highest Variance in Reported Marks
CompanyNormalized Std Dev5$ Weighted AvgMaxMin
Rad Power.60$0.55$0.95$0.20
DNA Script.36$221.43$257.77$45.45
Grammarly.28$18.42$27.80$15.51
MasterClass.24$4.38$5.36$3.30
ABL Space.18$0.64$0.85$0.39

5 Normalized Standard Deviation is used to express the measure of spread across reported marks and allows for comparison between companies independent of their price per share based on a dollar-weighted average.

This period, Rad Power ($0.20 - $0.95) saw the highest share price variance across funds followed by DNA Script ($45.45 - $257.77) and Grammarly ($15.51 - $27.80).

Positive Trend Reversal6 (# = consecutive prior qtrs marked down or flat)
Negative Trend Reversal7 (# = consecutive prior qtrs marked up or flat)
Positive Trend Reversal6 (# = consecutive prior qtrs marked down or flat)
Color Genomics
11
FLEXE
10
Farmers Business Network
8
goPuff
8
Negative Trend Reversal7 (# = consecutive prior qtrs marked up or flat)
Faraday Pharma
9
Clio
4
Honor Tech
4
Tenstorrent
4

6 Positive Trend Reversal reflects an individual holding marked up after consecutive quarterly periods marked down or flat
7 Negative Trend Reversal reflects an individual holding marked down after consecutive quarterly periods marked up or flat

Color Genomics saw its first positive reversal in eleven quarters while FLEXE saw its first positive reversal in ten quarters. Faraday Pharma saw its first negative reversal in nine quarters while Clio, Honor Tech, and Tenstorrent saw their first negative reversals in four quarters.

Disclaimer

This report is based on data reported by 300+ funds and $58+ billion of value. Many holders of private company shares do not report their holding values and are thus not included in this report’s dataset. Further, many venture-backed private companies are not held by any reporting funds and are thus not included in this report. As such, this report should not be construed as providing a complete picture of shareholder sentiment or venture-backed private company performance. This report does not constitute investment advice or a "research report" as defined by FINRA Rules.

The “ZX Index Value” is derived by applying proprietary weightings to the order flow data collected for the stated period (both bids and asks), based on the order type (firm order or indication of interest) and whether the order has been executed, with greater weight given to more recent orders.

Zanbato, Inc. (“Zanbato”) prepares and disseminates market information about venture-backed private company securities, and the current bids and offers for those securities listed on the ATS operated by Zanbato (“ZX”). The information provided in this report has been prepared by sales, trading, or other non-research functions. Pricing indications and macro commentary are provided for information purposes only. This report is not intended to assess the individual merits of a particular investment or strategy, does not constitute a recommendation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. This report does not constitute investment advice. Certain information in this report has been obtained from third party sources and, while such information is believed by Zanbato to be reliable, it has not been independently verified by Zanbato and Zanbato shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with any use of, or reliance on, such third party information. Furthermore, the information contained in this report may not be current due to, among other things, changes in the financial markets or economic environment. Zanbato does not, and has no obligation to, update any such information contained in this report. Any prices or quotations contained herein are indicative only, do not represent firm quotes as to either price or size and should not be used for valuation purposes.

yukacon_arrow_up_right